Potentially lifesaving treatment for rare cancer patients that costs tens of thousands of dollars will be slashed to just $25 ...
Merck beats Q4 earnings on Keytruda strength, but 2026 guidance disappoints amid patent expirations and weaker Gardasil sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results